Fluid Teardowns — Nº 004
One famous face.
$200M in 18 months.
A $1B war chest.
IM8 is David Beckham's supplement brand — and it went from launch to $200M+ in eighteen months, then raised a billion dollars to pour into acquisition. One sachet, 90 ingredients, and a machine built to scale globally. Here's the teardown.
A supplement that launched at the end of 2024 has already done north of $200 million and just raised a billion dollars — not to build a product, but to buy customers. That's the first thing that should stop you about IM8. This isn't a slow-burn wellness brand. It's a celebrity, a science story, and a subscription funnel, strapped to a war chest and an AI ad engine. Here's exactly how the machine is built.
By the end you'll have the seven plays behind $200M+ in eighteen months and a $1B growth raise — each with a "steal this" you can run tomorrow.
The receipts — revenue on a rocket
Public filings & guidance · annualized run-rateA celebrity, a science story, and a subscription.
IM8 is the wellness brand of David Beckham — not as a paid face, but as a co-founding partner — built by the NASDAQ-listed health company Prenetics. It launched in December 2024 with a single pitch: one daily sachet, 90 ingredients, replaces your entire supplement stack. Eighteen months later it's cleared $200M+, guided to $210–220M for 2026, and secured a $1 billion growth raise aimed squarely at scaling customer acquisition.
Strip away the celebrity and the science, and the engine is simple:
"Borrow trust, sell simplicity, subscribe them, then buy the next customer at scale."The IM8 operating principle
Their storefront, captured live.
Seven plays every wellness brand should copy.
The co-founder is the product, not the poster
David Beckham didn't lend his face to IM8 — he co-founded it. That distinction is the whole trust play. It's "the Beckham Formula," "the Beckham Stack," "Welcome from David." A global sports icon vouching as an owner reads completely differently than an endorsement, and it hands a brand-new supplement instant, borrowed credibility on a planetary scale.
If a name is going to front your brand, make them a stakeholder, not a spokesperson. Ownership reads as belief. The audience can tell the difference — and so can the algorithm.
Stack authority until the price feels obvious
IM8 doesn't argue it's worth $79 a month — it surrounds you with proof until the number stops mattering: "Mayo Clinic & NASA," "clinically proven," NSF Certified for Sport, third-party tested, 22,104 reviews, 53M+ servings, and "306 clinicians share it without compensation." Each badge is small; together they manufacture the feeling that skipping it would be irresponsible.
Don't win the price argument — dissolve it. Layer third-party certs, real reviews, and expert validation until the customer's question shifts from "is it worth it?" to "can I afford not to?"
Sell subtraction — replace the whole shelf
Most supplements ask you to add one more thing. IM8 sells the opposite: "One sachet replaces 16+ supplements for $2.61 a day." They price against the cluttered, expensive shelf you already own — not against a greens powder. Framed that way, $79/mo isn't a new cost, it's a consolidation and a saving. Simplicity is the feature; the price comparison is the close.
Anchor your price against the mess you replace, not the category you're in. "Instead of 16 bottles" beats "another supplement" every time. Sell the delete key.
Subscription-first, buried under value
The default isn't a jar — it's a 90-day subscription at $78/mo (30% off), and the offer buries every objection under a stack: a free $89 welcome kit, a luxe mixer and bottle, a "transformation program," a discounted biomarker blood test, a 90-day money-back guarantee. You're not deciding whether to buy a powder; you're deciding whether to join a program. That's how a consumable becomes recurring, compounding revenue.
Make the subscription the default and load the first order with gifts worth more than the price. When the free stuff outweighs the cost, "subscribe" becomes the rational choice, not the risky one.
Ride the longevity wave with a proprietary mechanism
IM8 didn't just enter the greens category — it planted a flag in longevity, the biggest story in wellness. Its second product, Daily Ultimate Longevity, is marketed as the "first supplement to target all 12 hallmarks of aging" via a proprietary "5-Complex System." A named, ownable mechanism turns a commodity (powdered nutrients) into a category of one.
Attach your product to the wave your market is already riding, then give it a named, proprietary mechanism. "Targets the 12 hallmarks of aging" sells; "has good ingredients" doesn't.
Run creative like software — AI ads at global scale
Here's the modern part. IM8 runs an AI-native ad engine that continuously creates, tests, and rotates thousands of ads simultaneously across 43 countries. It's Arrae's "treat creative like inventory" — automated. Instead of a team hand-building winners, a system spins up variations, kills losers, and scales winners around the clock, in dozens of markets at once. Creative volume stops being a headcount problem.
Treat ad creative as a system, not a project. Even a lightweight version — templated variations, fast testing, ruthless killing of losers — lets a small team produce the ad volume that used to require an agency.
Raise capital as an acquisition weapon
Most brands raise to build. IM8 raised to buy customers. The $1B came from General Catalyst's Customer Value Fund — capital structured specifically to finance acquisition against future lifetime value. Pair that with a high-AOV subscription and an AI ad engine, and you get a machine that can outspend everyone on the first purchase because it knows what the second, third, and tenth are worth. Capital becomes the moat.
Know your LTV cold, then fund acquisition against it. You don't have to raise a billion — but the brand that can confidently spend the most to acquire a customer, and survive it, usually wins the category.
The part most breakdowns skip…
Big claims and borrowed money are both leverage — and both risk.
Be clear-eyed. "Replace 16 supplements," "clinically proven," "targets the 12 hallmarks of aging," "Mayo Clinic & NASA" — this is exactly the language the FTC and FDA scrutinize on dietary supplements, where structure-function claims must be carefully substantiated and "clinically proven" is a loaded phrase. The "306 clinicians recommend it" mechanic is clever but the kind of thing regulators probe. And the business model leans hard on debt-funded paid acquisition: a $1B war chest only works if the LTV math holds — if CAC rises or retention slips, that leverage cuts the other way. Bold claims and borrowed money both amplify whatever's underneath them.
Tear off this page.
The IM8 playbook on one screen.
Trust, a subscription, and a checkout you own. Fluid runs it.
A face people believe, an offer that buries the objection, recurring revenue, and creative at scale — every play here is an operating-system problem. That's what we build.